Guardant Health (GH) announced it has reached a strategic agreement with LabFlorida/SunDx Labs to provide residents of senior living communities access to Guardant Shield, the first blood test approved by the FDA as a primary screening option for colorectal cancer. As part of the agreement, LabFlorida will serve as the exclusive distributor to senior living communities throughout Florida. LabFlorida/SunDX provides premier concierge-style lab testing, tailored specifically for assisted and independent living and homebound patients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health: Buy Rating Maintained Despite Disappointing Shield V2 Data, Strong Market Position Justifies Optimism
- Guardant Health price target raised to $70 from $65 at BTIG, remains Top Pick
- Guardant Health: Strong Market Position and Optimistic Outlook with Raised Price Target
- Guardant Health down 7% after reporting results of Shield V2 algorithm
- Guardant Health stock decline after data a ‘bit’ overdone, says Raymond James